Gan & Lee Pharmaceuticals’ glargine insulin injection receives marketing authorization from the European Commission
January 15, 2026
Source: drugdu
79
January 14th that Gan & Lee Pharmaceuticals...(603087) announced that the company and its wholly-owned European subsidiary, Gan & Lee Pharmaceuticals Europe Ltd., recently received a notification from the European Commission that the company's product, insulin glargine injection (trade name: Ondibta), has obtained marketing authorization in the European Union, Iceland, Liechtenstein and Norway for the treatment of diabetes in adults, adolescents and children aged 2 years and older.
https://finance.eastmoney.com/a/202601143619110685.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Kanghua Biologics Faces Formidable Challenges in mRNA Vaccine Development February 6, 2026
- Aligning with international standards! Aidea Pharma obtains Tanzania’s ML3 GMP certification February 5, 2026
- Shijiazhuang Pharmaceutical Group’s clopidogrel emulsion injection has received a drug registration certificate. February 5, 2026
- Human Coagulation Factor IX Drug Registration and Marketing Authorization Application Accepted February 5, 2026
- HX111 completes first patient dosing in Phase I clinical trial February 5, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
